Search results
Results from the WOW.Com Content Network
Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S ...
Basal insulin such as Levemir is a type of long-acting insulin injected once or twice a day as opposed to rapid, short, or intermediate-acting insulin. It is often used by people with Type 1 ...
The top of executive of Novo Nordisk told a Senate panel Tuesday it was a "difficult choice" to discontinue the long-acting insulin Levemir but he had to do so because of market forces.
Insulin detemir, sold under the brand name Levemir among others, is a long-acting modified form of medical insulin used to treat both type 1 and type 2 diabetes. [6] It is used by injection under the skin . [ 6 ]
Novo Nordisk created insulin detemir and markets it under the trade name Levemir as a long-lasting insulin analogue for maintaining the basal level of insulin. [1] [5] The basal level of insulin may be maintained for up to 20 hours, but the time is affected by the size of the injected dose.
Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza. [1]
Levemir's U.S. sales were 1.27 billion Danish crowns ($185.6 million) in 2023. Sales of Novo's other long-acting insulin Tresiba were 1.33 billion crowns last year. ($1 = 0.9172 euros)
Some side effects are hypoglycemia (low blood sugar), hypokalemia (low blood potassium), and allergic reactions. [6] Allergy to insulin affected about 2% of people, of which most reactions are not due to the insulin itself but to preservatives added to insulin such as zinc, protamine, and meta-cresol.